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KLF1 (formerly known as EKLF) regulates the development of erythroid cells from bi-potent progenitor cells via the
transcriptional activation of a diverse set of genes. Mice lacking Klf1 die in utero prior to E15 from severe anemia due to the
inadequate expression of genes controlling hemoglobin production, cell membrane and cytoskeletal integrity, and the cell
cycle. We have recently described the full repertoire of KLF1 binding sites in vivo by performing KLF1 ChIP-seq in primary
erythroid tissue (E14.5 fetal liver). Here we describe the KLF1-dependent erythroid transcriptome by comparing mRNA-
seq from Klf1 +/+ and Klf1 –/– erythroid tissue. This has revealed novel target genes not previously obtainable by traditional
microarray technology, and provided novel insights into the function of KLF1 as a transcriptional activator. We define a cis-
regulatory module bound by KLF1, GATA1, TAL1, and EP300 that coordinates a core set of erythroid genes. We also
describe a novel set of erythroid-specific promoters that drive high-level expression of otherwise ubiquitously expressed
genes in erythroid cells. Our study has identified two novel lncRNAs that are dynamically expressed during erythroid
differentiation, and discovered a role for KLF1 in directing apoptotic gene expression to drive the terminal stages of
erythroid maturation.
[Supplemental material is available for this article.]
The erythroid transcription factor KLF1 (formerly known as EKLF)
is essential for erythropoiesis in mouse and contains pathogenic
mutations in some human cases of congenital dyserythropoietic
anemia (CDA; OMIM 613673) (Nuez et al. 1995; Perkins et al.
1995; Arnaud et al. 2010; Singleton et al. 2011). Loss-of-function
mutations in human KLF1 also underlie the InLu blood group
phenotype, result in elevated levels of fetal hemoglobin, and lead
to increased levels of zinc protoporphyrin (Singleton et al. 2008;
Borg et al. 2010; Satta et al. 2011). Studies of global gene regulation
by KLF1 using traditional oligonucleotide microarray technology
and, more recently, ChIP-seq technology have provided valuable
insights into the KLF1-dependent erythroid transcriptome (Drissen
et al. 2005; Hodge et al. 2006; Tallack et al. 2010; Pilon et al. 2011).
These studies have begun to reveal the extensive repertoire of KLF1
target genes that includes not only genes responsible for the pro-
duction of hemoglobin but also regulators of the cell cycle, mem-
brane and cytoskeletal components, and regulators of apoptosis
(Tallack and Perkins 2010; Siatecka and Bieker 2011).
The expression of Klf1 is restricted to erythroid cells and their
precursor, themegakaryocyte-erythrocyte progenitor (MEP).Klf1/
mice succumb to anemia and die by E15, which can be partly ex-
plained by its roles in the activation of gene expression for Hbb-b1
(also known as b-globin), the cell cycle regulators E2f2 and E2f4,
and components of the erythroid cytoskeleton such as Epb4.9 (also
known as dematin) (Miller and Bieker 1993; Nuez et al. 1995;
Perkins et al. 1995; Drissen et al. 2005; Hodge et al. 2006; Frontelo
et al. 2007; Pilon et al. 2008; Tallack et al. 2009). Loss of these to-
gether results in reduced hemoglobin production, impaired pro-
liferation, and erythrocyte fragility, respectively. However, the few
direct KLF1 target genes that have been described are not sufficient
to explain all of the roles that KLF1 plays in erythroid differen-
tiation and the pathology of human CDA resulting from KLF1
mutations.
The control of erythroid differentiation has been extensively
studied, particularly with regard to the roles of extracellular cyto-
kine signaling and transcription factor proteins (Hattangadi et al.
2011). However, it is only recently that we have begun to un-
derstand some of the processes that are unique to erythroid de-
velopment such as the process of enucleation ( Ji et al. 2011). Re-
cent studies have described that enucleation is controlled by genes
that regulate histone deacetylation to condense chromatin such as
Hdac2, genes that underpin vesicle trafficking to create a cleft be-
tween the nucleus and cytoplasm, and genes that govern the for-
mation of a contractile actin ring to ‘‘pinch off’’ the nucleus ( Ji et al.
2008, 2010; Keerthivasan et al. 2010). Interestingly, some of these
processes are not unique to enucleation but are also important
steps in the process of apoptosis (Testa 2004; Hattangadi et al.
2011). Additionally, the loss of components of the apoptotic ma-
chinery such as Bcl2l1 (also known as BclX) leads to a failure in
terminal erythroid differentiation (Motoyama et al. 1995; Wagner
et al. 2000).
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The aimof this studywas to build uponour previousChIP-seq
study describing the in vivo occupancy of KLF1 in erythroid cells
(Tallack et al. 2010). We have used next-generation DNA se-
quencing to describe a more comprehensive list of likely KLF1
target genes than was previously possible using oligonucleotide
microarrays. By combining these data sets, we have gained deeper
insights into how KLF1 works as a transcription factor in vivo,
and have described for the first time a set of novel erythroid-
specific promoters that are KLF1-dependent. Our data have also
revealed two novel long noncoding RNAs (lncRNAs). We suggest
that these, along with regulation of the apoptotic machinery,
might be critical KLF1-regulated processes driving terminal ery-
throid differentiation.
Results
KLF1 activates an extensive erythroid gene expression program
In order to comprehensively define the set of direct KLF1 target
genes during erythroid development, we previously performed
KLF1 ChIP-seq on E14.5 primary fetal liver (Tallack et al. 2010).
However, a limitation of this study was that at the time of publi-
cation, the set of differentially regulated KLF1 genes for compari-
son had been determined using oligonucleotide microarray tech-
nology and contained only the ‘‘lowest hanging fruit’’ (Drissen
et al. 2005; Hodge et al. 2006; Pilon et al. 2008; Tallack et al. 2010).
Hence we have now used next-generation DNA sequencing, a
highly sensitive and unbiased approach, to define for the first time
the comprehensive KLF1-dependent erythroid transcriptome.
We performedmRNA-seq using the IlluminaGAII sequencing
platform for three independent biological samples of Klf1+/+ and
Klf1/ fetal liver. We collected greater than 20 million sequence
reads for each sample and mapped these to the mouse genome
(mm9). To determine a highly sensitive set of KLF1-dependent
genes, we performed a differential gene expression analysis using
Cuffdiff software (Trapnell et al. 2010) and RefSeq gene annota-
tions (Pruitt et al. 2007) that allowed us to describe 690 KLF1
‘‘activated’’ genes (significantly greater expression in Klf1+/+,
Benjamini-Hochberg–corrected P < 0.05) and 118 KLF1 ‘‘repressed’’
genes (significantly lower expression in Klf1+/+; Benjamini-Hochberg–
corrected P < 0.05) (Fig. 1A; Supplemental Table S1). The use
of next-generation DNA sequencing has allowed us to identify
likely KLF1 target genes across five orders of magnitude of gene
expression as judged by the FPKM (fragments per kilobase of exon
per million fragments mapped) metric (Fig. 1A). This analysis
identified previously known KLF1 target genes such as Epb4.9,
Klf3 (previously known as Bklf ), and E2f2 as differentially expressed;
however, the power of this approach is likely to be in the identifica-
tionof genes fitting into the LOWexpression category (mean FPKM <
10 for Klf1+/+) as KLF1-dependent (Fig. 1A; Drissen et al. 2005;
Hodge et al. 2006; Funnell et al. 2007; Pilon et al. 2008; Tallack
et al. 2009).
Our identification of differentially expressed genes bymRNA-
seq is consistent with our previous oligonucleotide microarray
study (Supplemental Fig. S1); however, it is worth noting that of
the 808 genes identified by this approach (690 KLF1 ‘‘activated’’
and 118 KLF1 ‘‘repressed’’), only 122 were also identified as dif-
ferentially expressed by Hodge et al. (2006; Supplemental Table S2).
We conclude that this is likely to be due to the increased sensitivity
ofmRNA-seq as well as the biases in gene representation and probe
sensitivity that are inherent for oligonucleotide microarrays. We
further validated ourmRNA-seq data by comparing it to previously
performed qRT-PCR for the direct KLF1 target genes E2f2, E2f4, and
Cdkn2c (also known as p18INK4c) (Fig. 1B,C; Tallack et al. 2007,
2009). We also performed additional qRT-PCR for genes not found
to be significantly differentially expressed, Myc and Rb1, and
gained a similar result (Fig. 1B,C).
KLF1 has been suggested to operate as both a transcriptional
activator and a transcriptional repressor depending on both the
cellular context and target gene (Feng et al. 1994; Chen and Bieker
2001, 2004; Drissen et al. 2005; Hodge et al. 2006; Siatecka et al.
2007). Interestingly, we found overrepresentation of the CACC
motif (specifically the JASPAR KLF4 motif) at both KLF1 ‘‘acti-
vated’’ and KLF1 ‘‘repressed’’ gene promoters (within 500 bp)
(Supplemental Fig. S2). We additionally found an overrepresen-
tation of an NFYA motif, resembling a CCAAT box, in both sets of
gene promoters (Supplemental Fig. S2). However, ChIP-seq for
KLF1 shows occupancy within the promoter (1000 bp) of a single
KLF1 ‘‘repressed’’ gene (out of 118). Thus, we suggest CACCmotifs
in these promoters are likely to bind repressor KLFs such as KLF3,
KLF8, and KLF12. Indeed, Klf3 and Klf8 are known direct targets of
KLF1 (Funnell et al. 2007; Eaton et al. 2008).Wehave not been able
to successfully ChIP these repressor KLFs due to lack of antibodies.
We sought to gain additional insight into how KLF1 might
operate as an activator or a repressor by pairing each of the 945
high-confidence in vivo KLF1 binding sites (peaks) we previously
identified with the transcription start sites (TSSs) of the closest
‘‘activated’’ or ‘‘repressed’’ gene (Supplemental Table S3). Each of
these KLF1 peak–TSS pairs represents a possible trans interaction
regulating the erythroid transcriptome. We calculated and plotted
the cumulative frequency distributions of the genomic distances
for each of these interactions compared with the distributions for
10 randomly selected sets of TSSs of the same size as the controls
(Fig. 1D,E). We noted that the distribution for KLF1 peak–‘‘acti-
vated’’ TSS pairs was significantly different to the controls; how-
ever, the KLF1 peak–‘‘repressed’’ TSS pairs distribution was identi-
cal to the control simulated distributions. This suggests that the
distance between the KLF1 peaks and genes that show a reduced
expression in Klf1/ erythroid tissue is on average much closer
thanwould be expected by chance, consistent with the hypothesis
that KLF1 acts as an activator (Fig. 1D). The fact that the same
distribution calculated between KLF1 peaks and ‘‘repressed’’ genes
is identical to the control does suggest KLF1 acts as a repressor very
infrequently in erythroid cells. It does not exclude occasional re-
pression of specific transcripts or repression of megakaryocyte
genes such as Fli1 inMEPs that represent just 6%of E14.5 fetal liver
cells (Fig. 1E; Starck et al. 2003; Papathanasiou et al. 2010).
Insights into KLF1 cooperation in vivo
We previously described a significant overlap in in vivo binding
between KLF1 and another critical erythroid transcription factor,
GATA1 (Tallack et al. 2010). At the time of this publication, the
same analysis was also performed for an additional erythroid
transcription factor, TAL1 (formerly known as SCL) using the best
available ChIP-seq data set (Wilson et al. 2009). A more suitable
ChIP-seq data set for erythroid TAL1 binding has since been pub-
lished, and we assessed the overlap between this data set and the
previously used data sets for KLF1 and GATA1 (Cheng et al. 2009;
Kassouf et al. 2010; Tallack et al. 2010). We found a set of 119 re-
gions in themouse genome (mm9) that are occupied by these three
factors (Fig. 2A; Supplemental Table S4). We suggest that these
regions are likely to be promoters and/or enhancers that drive
specific and potent erythroid gene expression.
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The activation of target genes by KLF1 is likely to be largely
dependent on its direct recruitment of transcriptional coactivators
such as EP300/CREBBP (Zhang et al. 2001). We took advantage of
a recent study describing EP300 coactivator occupancy in murine
erythroleukemia (MEL) cells to determine sites of in vivo KLF1
binding that are shared by EP300 (Fig. 2B; Birney et al. 2007).
Interestingly, of the 945 KLF1 binding sites, only around a one-
third (305 of 945) are also bound by EP300 (Fig. 2B). This was
Figure 1. mRNA-seq reveals a comprehensive set of KLF1 activated genes. (A) A scatter plot representation of mRNA-seq expression data. Each data point
represents a single RefSeq gene plotted according to the mean fold change between Klf1 genotypes (x-axis) and the mean Klf1+/+ expression (y-axis). The
identity of several data points is indicated for reference. Vertical red lines indicate the 1.5-fold differential expression cutoff to define the KLF1 ‘‘activated’’
(decreased expression in Klf1/ samples) and KLF1 ‘‘repressed’’ (increased expression in Klf1/ samples). Geneswere further sorted according to theirmean
Klf1+/+ expression into high, intermediate, and low expression categories. This data set is available as Supplemental Table S1. (B) mRNA-seq quantification by
FPKMvalues. Eachbar represents themean FPKM + 95%confidence interval for three independent biological replicates. (C ) qRT-PCR validation ofmRNA-seq
data. Each bar represents the mean + SEM for at least three independent biological replicates. Gene expression was normalized to the housekeeping gene
HPRT and wild-type expression level. Klf1+/? is used to indicate that both Klf1+/+ and Klf1+/ samples were considered together. (D) Cumulative frequency
distribution for the distances between KLF1 ‘‘activated’’ TSSs and KLF1 ChIP-seq peak locations (solid green line). The average distribution for 10 randomly
simulated controls is also shown (dashed green line). (E ) Cumulative frequency distribution for the distances between KLF1 ‘‘repressed’’ TSSs and KLF1 ChIP-
seq peak locations (solid red line). The average distribution for 10 randomly simulated controls is also shown (dashed red line).
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irrespective of whether the KLF1 binding site was at a ‘‘classical
promoter’’ location (#1000 bp upstream of a TSS, eight of 23 sites
shared with EP300) or at a nonpromoter regulatory element (299
of 915 sites shared with EP300).
This EP300 ChIP-seq data also provided some useful insight
into the function of particular KLF1 bound regions. For example,
we have previously described intragenic regions of the E2f2 and
E2f4 loci that act as erythroid enhancers (Tallack et al. 2009). The
EP300 ChIP-seq data of Birney et al. (2007) shows that this is likely
to be in part via recruitment of EP300
since EP300 binding is strong at these
regions (data not shown). Hence we de-
cided to test a KLF1-bound region that
was not found to bind EP300 by ChIP-
seq. We cloned and tested an intergenic
region 40 kb downstream from the Klf3
locus for erythroid enhancer activity
(Supplemental Fig. S3). Although this re-
gion binds KLF1 very strongly (peak
height, 30), it fails to act as an enhancer
inMEL cells (unlike the enhancers of E2f2
and E2f4). It will be interesting to de-
termine the function of KLF1 at this re-
gion (Klf3 +40e) (Supplemental Fig. S3)
and similar regions that do not cobind
EP300, although this is not trivial.
We also examined the representa-
tion of specific transcription factor DNA
motifs in the two sets of peaks (KLF1Only
and EP300 Shared) using MEME-ChIP
(Fig. 2B;Machanick andBailey 2011). Not
surprisingly, we found the presence of
the CACCmotif (59-CCMCRCCCN-39) in
both sets of peaks, suggesting that KLF1
truly binds both sets. The EP300 Shared
set of peaks also contained a significant
overrepresentation of the GATA1 (59-
WGATAR-39) binding motif and a motif
resembling an E-Box, presumably capa-
ble of binding TAL1 (Fig. 2B). Central
motif enrichment analysis (CMEA) using
CentriMo also showed that GATA1 and
TAL1 binding motifs are more highly
enriched in the EP300 Shared set of KLF1
binding sites compared with the KLF1
Only sites (Supplemental Fig. S4; Bailey
and Machanick 2012). These results
suggest that the cooperative binding of
KLF1 together with GATA1 and/or TAL1
serves to more strongly recruit EP300 to
the DNA as might be expected. We fur-
ther tested this hypothesis by looking at
the overlap between the KLF1-GATA1-
TAL1 three-way sites (three-way overlap,
119 sites) with EP300 (Fig. 2C). The ma-
jority of the three-way overlap sites are
also bound by EP300 (75 of 119), con-
sistent with the hypothesis that regions
containing more than one of the factors
canmore effectively recruit EP300. These
regions are likely to represent a core cis-
regulatory module driving erythroid-
specific gene expression via the KLF1-GATA1-TAL1 transcription
factor network and associated factors. This DNA-bound complex
is likely to be a giant complex of proteins that includes LMO2,
LDB1, EP300, and probably manymore associated proteins (Soler
et al. 2010). We found no overrepresentation of other cis-motifs,
so other DNA binding transcription factors are not likely to par-
ticipate in the function of this core erythroid enhancer complex.
Since KLF1 peaks are on average closer to ‘‘activated’’ TSSs
than expected (Fig. 1D), we sought to determine if the presence of
Figure 2. KLF1 works co-operatively with GATA1, TAL1, and EP300 to activate genes. (A) Venn di-
agram showing the overlap between in vivo binding of KLF1 (Tallack et al. 2010), GATA1 (Cheng et al.
2009), and TAL1 (Kassouf et al. 2010) from erythroid tissue ChIP-seq. (B) Venn diagram showing the
overlap between in vivo binding of KLF1 (Tallack et al. 2010) and EP300 (Birney et al. 2007) from
erythroid tissue ChIP-seq. KLF1 peaks were separated into two categories, KLF1 only and EP300 shared,
as indicated, and subjected to motif enrichment analysis using MEME-ChIP. Significantly enriched
motifs for each set are shown together with the percentage of peaks in that category containing the
motif. (C ) Venn diagram showing the overlap between three-way overlap peaks (KLF1-GATA1-TAL1,
shown in A) and EP300 from erythroid tissue ChIP-seq. (D) Cumulative frequency distribution for the
distances between KLF1 ‘‘activated’’ TSSs and either KLF1 only peaks (green line) or EP300 shared peaks
(red line) as defined in B.
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EP300 affected this distribution, or in other words, ‘‘are KLF1–
EP300 Shared sites closer to TSSs than KLF1 Only sites?’’. We
measured the distance from each peak to the closest ‘‘activated’’
TSS for the KLF1Only (Fig. 2D, green line) and KLF1–EP300 Shared
(Fig. 2D, red line) sets of peaks and plotted the distributions. This
data indicates that on average KLF1–EP300 Shared peaks are closer
to ‘‘activated’’ genes than are KLF1Only peaks (Fig. 2D). Since KLF1
binding sites that do not recruit EP300 tend to be further from
TSSs, this suggests at least a subset of these sites might not be in-
volved in transcriptional activation at all. They are unlikely to be
artifacts as they frequently contain an extended CACC motif at
a high frequency (46%) (Fig. 2B).
KLF1 mRNA-seq reveals a set of novel erythroid gene
promoters
We and others have previously identified that KLF1, GATA1, and
TAL1 frequently bind target genes at sites other than the pro-
moter, particularly within introns (Cheng et al. 2009; Kassouf
et al. 2010; Tallack et al. 2010). We used our list of 119 three-way
overlap sites as a starting point to look for novel erythroid pro-
moters that might serve to drive high levels of erythroid-specific
expression (Supplemental Table S4). We identified novel pro-
moters for seven genes using our mRNA-seq data, particularly
making use of splice junction reads (reads that are split when
mapped to the genome), some of which are further supported by
mouse ESTs or CAGE tag clusters (Table 1; Supplemental Fig. S5).
This list includes the gene encoding the first two enzymes of the
heme synthesis pathway, Alas2 and Alad (Table 1). The start of
translation for these two genes begins in exon 2 of the RefSeq
transcripts, allowing for the use of novel erythroid-specific pro-
moters that will produce the same protein (Fig. 3A,B). Indeed,
ChIP-seq data for KLF1, GATA1, and TAL1 show binding of all
three factors within the first intron for both Alas2 and Alad (Fig.
3A,B, vertical green stripes).
Our mRNA-seq data for Alas2 indicate that the majority of
erythroid transcription begins at exon 2 and that in this instance
the transcription factor binding within the first intron resembles
canonical promoter binding for these transcription factors (Fig. 3A,
Klf1+/+ in orange, Klf1/ in light blue, declared transcripts in red).
Very few reads from our mRNA-seq map to RefSeq exon 1 of Alas2
compared with the large number mapping to exon 2 (Fig. 3A,
exons 1 and 2 highlighted by vertical stripes). To support this ob-
servation, we determined the ratio of reads mapping to either the
RefSeq exon 1 (Fig. 3A, labeled Ref) or the novel erythroid exon 1
(Fig. 3A, labeled Ery, RefSeq exon 2) compared with exon 2 of each
transcript, and found these ratios to be significantly different (Fig.
3A, bar chart). Our mRNA-seq data also confirm the KLF1 de-
pendance of Alas2 gene expression, which is roughly threefold
lower in Klf1/ fetal liver samples (Fig. 3A, cf. light blue track and
orange track; Table 1). We also noted that the coactivator EP300 is
recruited to this novel promoter, presumably by the binding of
KLF1, GATA1, and TAL1 (Fig. 3A, dark blue track).
Similarly, erythroid expression of Alad does not begin at exon
1 of the RefSeq transcript (Fig. 3B). However, in the case of Alad, we
have uncovered a completely novel first exon beginning imme-
diately upstream of KLF1-GATA1-TAL1 binding (Fig. 3B, vertical
green stripe, declared transcripts in red). Likewise, expression of
Alad is highly dependent of KLF1, being fivefold lower in theKlf1/
samples (Fig. 3B, cf. light blue track and orange track; Table 1). We
also found the exon 1:exon 2 ratios for the RefSeq exon 1 and novel
erythroid exon 1 to be significantly different, suggesting that the
novel erythroid exon 1 was likely to be dominant in erythropoiesis
(Fig. 3B, bar chart).
In the cases of Alas2 and Alad, these genes are broadly
expressed since heme is a cofactor for a large number of hemo-
proteins, such as myoglobin and the cytochromes (Reedy et al.
2008). However, their demand in erythroid tissues is far greater
since hemoglobin is so abundant. Hence it seems reasonable that
these genes have evolved an alternative ‘‘switch’’ to control their
erythroid expression. This has also been shown for the transcrip-
tional repressor Klf3 (Funnell et al. 2007). To test this hypothesis in
human tissue, we analyzed the expression of each of the genes we
identified as having novel erythroid promoters using the human
gene atlas gene expression set containing 79 different tissues, one
of which was ‘‘CD71 positive early erythroid’’ (Su et al. 2004;
Vaquerizas et al. 2009). The gene atlas data support our hypothesis
since each of the genes shows a fairly broad range of expression,
with the two erythroid samples clearly expressed most highly and
often for multiple probes on the microarray (Fig. 3C, erythroid as
red dots, all other tissues black dots). We anticipated genes such as
Alas2,Alad,Urod, and Steap3would show this pattern of expression
due to their crucial roles in heme synthesis and iron procurement
by erythroid cells. However, we have also uncovered three addi-
tional genes, Ubac1, Ube2v1, and Itsn1 that are highly expressed
in erythroid tissue, dependent on KLF1, GATA1, and TAL1 for
their expression and have a relatively unknown function (Fig. 3C;
Table 1). It will be of great interest to determine the roles that
these genes play in erythropoiesis.
Erythroid lncRNAs controlled by KLF1
While a great deal is known of the contribution of microRNAs
(miRs) to erythropoiesis, very little is known of the contribution of
other species of nonprotein coding RNAs, particularly those clas-
sified as lncRNAs (Rasmussen et al. 2010; Hattangadi et al. 2011;
Zhang et al. 2011). We have used our mRNA-seq data to identify
two novel lncRNAs that are previously uncharacterized, KLF1-
dependent, and expressed at the terminal stages of erythroid dif-
ferentiation. We have designated these lncRNAs Lincred1 and
Lincred2 for long intergenic noncoding RNA of erythroid differ-
entiation (Fig. 4A,B; Supplemental Fig. S6). The presence of ChIP-
seq peaks for KLF1, GATA1, and TAL1 at or near the promoters of
Lincred1 and Lincred2 suggests they are likely to be functional
during erythroid differentiation (Fig. 4A,B). The transcripts we
have declared to be Lincred1 and Lincred2 were compiled using
Cufflinks software using splice junction tags to define exons (Fig.
4A,B, red tracks). Lincred1 has two alternative transcripts we des-
ignated Lincred1-giant and Lincred1-dwarf to reflect their relative
lengths.
The quantification of mRNA-seq data indicates that Lincred1
(giant and dwarf) and Lincred2 are both KLF1-dependent transcripts
(Fig. 4C). We tested the Lincred transcripts for possible open read-
ing frames (ORFs) to determine if they truly were likely to be
nonprotein coding. Neither Lincred1 nor Lincred2 contains any
significant ORFs that would encode a protein of greater than 100
amino acids, providing further evidence that they are lncRNAs
(data not shown). We confirmed the KLF1 dependence of Lincred1
and Lincred2 expression by qRT-PCR using specific primers (Lincred1
primers amplify both isoforms) and observed a Klf1 gene dosage
effect on their expression (Fig. 4D).
In order to infer possible functions for Lincred1 and Lincred2
in erythroid differentiation, we sorted E13.5 fetal liver cells into
five populations (R1–R5) using the cell surface markers CD71 and
The KLF1-dependent erythroid transcriptome
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TER119, as performed previously (Fig. 4E; Zhang et al. 2003). Both
Lincred1 and Lincred2 have almost an undetectable expression in
erythroid progenitors (R1 and R2) and a pattern of increasing ex-
pression in the terminal stages of erythroid differentiation (highest
in R5) (Fig. 4F,G). This expression pattern mirrors the expression
pattern of Klf1 itself and provides some evidence that Lincred1
and Lincred2 might be involved in regulating processes at play
during terminal erythroid differentiation, although loss- and
gain-of-function studies are required to confirm this (Supple-
mental Fig. S7).
KLF1 as a regulator of the apoptotic program
mRNA-seq has provided many additional KLF1-dependent genes
compared to previous oligonucleotide microarray studies, so we
sought to look broadly for unappreciated functions for KLF1 in
erythropoiesis. We performed Gene Ontology (GO) analysis us-
ing the online tool DAVID to look for enriched terms in the 690
KLF1 ‘‘activated’’ and 118 KLF1 ‘‘repressed’’ genes (Supplemental
Table S5). In addition to terms we expected to find such as eryth-
ropoiesis and heme biosynthesis, we found terms relating to apo-
ptosis were enriched in our KLF1 ‘‘activated’’ gene set (Supple-
mental Table S5).
This result prompted us to look closer at specific apoptotic
genes that might be direct KLF1 targets. We previously reported
that Bcl2l1 was likely to be a direct KLF1 target gene; hence, we
sought to confirm this by qRT-PCR (Tallack et al. 2010). Addi-
tionally, previous studies of apoptotic genes and erythropoiesis
had suggested that Bcl2l11 (formerly Bim) expression levels, in this
instance regulated by Zbtb7a (also known as Lrf and Pokemon),
were critical determinants of erythroid cell survival (Maeda et al.
2009). We found by qRT-PCR that expression of the anti-apoptotic
gene Bcl2l1 was significantly reduced in Klf1/ erythroid cells
(approximately twofold) (Fig. 5A) and that expression of the pro-
apoptotic gene Bcl2l11 was elevated (approximately 2.5-fold)
(Fig. 5A). Both of these genes have been previously shown to play
a role in erythropoiesis (Wagner et al. 2000; Maeda et al. 2009).
This suggested that the apoptotic gene expression programmight
be perturbed in the absence of Klf1.
We sought to determine if aberrant induction of apoptosis
was also a contributor to the severe anemia in Klf1/ mice. We
found evidence of the cleaved active 17-kD form of caspase 3 in
Klf1/ erythroid cells that was not present in either Klf1+/+ or
Klf1+/ cells (Fig. 5B). Traditionally, active caspase 3 drives apo-
ptosis, partly via cleavage of poly (ADP-ribose) polymerase family,
member 1 (PARP1). However, we did not find any evidence of in-
creased cleavage of PARP1 in Klf1/ cells (Fig. 5B).We additionally
looked for cleavage of GATA1 and TAL1 since these have been
reported to be targets of activated caspases in erythroid cells, but
we found no evidence that this was occurring (Supplemental Fig.
S8; De Maria et al. 1999; Zeuner et al. 2003). This might be due to
protection of GATA1 and TAL1 by the heat shock proteins HSPA1A
and HSPA1B, which have increased expression in Klf1/ cells
(Supplemental Fig. S8; Ribeil et al. 2007). Neither is a direct KLF1
target gene so up-regulation is indirect (data not shown). The latter
observation strongly suggests Klf1/ cells ‘‘sense’’ activated cas-
pases and up-regulate genes indirectly (such asHspa1a andHspa1b)
to provide protection against cell death.
Since we had observed Klf1/ cells to have a distorted ap-
optotic genetic program, we looked for further signs that apo-
ptosis might be occurring. We found no significant difference in
Annexin V staining at the cell surface between Klf1/ and Klf1+/+
cells (data not shown).We also used the terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay combined
with an erythroid cell surface marker (CD71) to determine if
apoptotic cell numbers were increased in Klf1/ tissue (Fig. 5C).
We found a slight increase in TUNEL-positive erythroid cells
in Klf1/ embryos (;0.5% Klf1+/+ vs. ;1.1% Klf1/) (Fig. 5C).
Despite an absence of significant apoptosis, we believe caspase
3 cleavage might derail normal erythroid differentiation since
these activated proteases could potentially digest many other
protein targets.
Discussion
In this study we have described the use of next-generation DNA
sequencing to gain a comprehensivedescription of KLF1-dependent
erythroid genes (Fig. 1A; Supplemental Table S1). The sensitivity of
mRNA-seq has allowed us to identify differentially expressed genes
between the Klf1/ and Klf1+/+ genotypes that were previously
missed by oligonucleotide microarray, particularly those that we
have assigned to the ‘‘low’’ expression category (Fig. 1A; Supple-
mental Table S1). We have compared these data to our previously
published work describing the in vivo chromatin occupancy of
KLF1 to begin to define KLF1 peak-TSS pairs, many of which are
likely to reflect in vivo KLF1 gene regulatory activities (Supple-
mental Table S3; Tallack et al. 2010). However, the assignment of
these KLF1 peak–TSS pairs is based upon a linear model of the ge-
nome and does not account for three-dimensional DNA looping or
the presence of nuclear transcription factories seeded by KLF1 and
RNA polymerase II (Drissen et al. 2004; Schoenfelder et al. 2010;
Eskiw and Fraser 2011). Nevertheless, this method has revealed
that KLF1 is likely to predominantly function as a transcriptional
activator in vivo and that in most cases the closest gene to an
Figure 3. Identification of a novel set of KLF1-GATA1-TAL1–dependent erythroid promoters. (A) An image of murine Alas2 from the UCSC Genome
Browser with tracks depicting a novel mechanism of erythroid gene regulation whereby transcription begins at RefSeq exon 2 (Ery TSS). The RefSeq gene
annotations (dark blue) are shown together with mRNA-seq transcripts defined using Cuffdiff (red). Representative tracks for a single Klf1/ and Klf1+/+
mRNA-seq sample are shown in light blue and orange, respectively, with bothmapped read density (wiggle) and splice junction information (all tracks are
shown in Supplemental Fig. S5). ChIP-seq tracks for KLF1, GATA1, and TAL1 are shown in maroon with peak calls underneath. CTCF and EP300 ChIP-seq
from the ENCODE consortium are shown in blue as well as a vertebrate conservation track (phyloP). Gray and green vertical lines are included to point out
RefSeq TSSs (Ref) and novel erythroid TSSs (Ery), respectively. Regions of multitranscription factor occupancy are also highlighted by a vertical green line.
(Bar chart) Quantification of relative promoter usage describing the ratio of RefSeq exon 1 counts or erythroid exon 1 counts relative to exon 2 for six
biological replicates. Data shown are the mean + SEM. (***) P < 0.001 by Student’s t-test. (B) An image of murine Alad from the UCSC Genome Browser
depicting a novel mechanism of erythroid gene regulation whereby transcription begins at a novel first exon residing within RefSeq intron 1 (Ery TSS). All
tracks are shown as above in A. The bar chart also shows quantification of relative promoter usage for either RefSeq exon 1 or the novel erythroid exon 1
compared to exon 2 for six biological replicates. Data shown are themean6 SEM. (***) P < 0.001 by Student’s t-test. (C ) Relative gene expression obtained
fromGene Expression Atlas for each of the genes described to use novel erythroid promoters (Table 1). Red dots are used to show the expression in the two
CD71+ early erythroid samples, while black dots show the expression in all other tissues of the atlas. The HG-U133A probe numbers are shown for each
gene since some genes are represented bymultiple probes. Klf3 serves as a positive control since it has previously been shown to be ubiquitously expressed
with greatest expression in erythroid cells (Funnell et al. 2007).
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occupied chromatin segment is unlikely to be the KLF1 target
gene, at least in terms of a linear genome (Fig. 1D,E). We did not
compare our mRNA-seq data to the recently published KLF1
ChIP-seq data of Pilon and colleagues (2011) since our bio-
informatic analysis of these data showed no evidence of direct,
sequence-specific binding by KLF1 in the ChIP-seq regions they
reported, (Supplemental Figs. S9, S10). In contrast, the same
analysis on our own previously published ChIP-seq study reveals
an enrichment of the KLF1 binding motif in regions declared as
peaks (Supplemental Fig. S10; Tallack et al. 2010). These analyses
are discussed in greater detail in the Supplemental Material ac-
companying this article.
We have taken advantage of other erythroid ChIP-seq studies
to define a core set of cis-regulatory modules, regions with KLF1,
GATA1 and TAL1 occupancy in close proximity (Fig. 2A; Supple-
mental Table S4). The majority of these regions are also occupied
by the transcriptional coactivator EP300 as might be expected
(Fig. 2C). However, we were surprised to find that many genomic
sites bound by KLF1 are not co-occupied by EP300 (Fig. 2B). These
sites still contain a significant overrepresentation of the KLF1
binding motif (46%), suggesting that they are real and that KLF1
binding is specific (Fig. 2B). We suggest KLF1 functions at these
sites in a EP300-independent manner. This is consistent with
the recent study of Mas et al. (2011) that describes the N-terminal
transactivation domain of KLF1 can bind to additional coac-
tivator proteins besides EP300.
We also undertook this study in part to address some of the
prevailing questions that have arisen from recent studies de-
scribing KLF1 in vivo chromatin occupancy on a global scale by
ChIP-seq (Tallack et al. 2010; Pilon et al. 2011). In particular, our
previous study as well as similar studies of GATA1, TAL1, and as-
sociated proteins has shown that many sites of chromatin occu-
pancy by erythroid transcription factors do not occur in proximal
promoter regions (Cheng et al. 2009; Kassouf et al. 2010; Soler et al.
2010; Tallack et al. 2010). In particular, these studies have identi-
fied a significant portion of the occupied chromatin regions are
actually the first introns of target genes. We hypothesized that
these regions might act as either novel erythroid-specific gene
promoters, or that these regions might act as enhancers that co-
operate with the gene promoter by DNA looping, as has been
suggested elsewhere (Magklara and Smith 2009; Alotaibi et al.
2010). Our mRNA-seq data have suggested that the former hy-
pothesis is true for many instances of intron 1 chromatin occu-
pancy (Table 1; Fig. 3). In the cases of Alas2, Alad, and Steap3, this
allows for a unique erythroid-specific transcriptional regulatory
input to drive high-level erythroid expressionwhile still producing
an identical protein output since the start of translation falls
downstream (Table 1; Fig. 3; Supplemental Fig. S5). The latter hy-
pothesis is also likely to be true since in the case of the cell cycle
regulator E2f2, a well-known KLF1 target gene, chromatin occu-
pancy occurswithin intron 1, yetwe cannot find any evidence that
this leads to transcription from a novel TSS by mRNA-seq (Tallack
et al. 2009).
ChIP-seq studies for KLF1, GATA1, and TAL1 have also de-
scribed a number of regions of chromatin occupancy for which
a target gene cannot be easily assigned due to their location in
regions devoid of likely target genes. Inmany cases, these regions
of chromatin occupancy are likely to be involved in long-range
chromatin looping, such as is well understood for the b-globin
LCR, or they might be essential to seed the formation of tran-
scription factories within the nucleus (Drissen et al. 2004;
Schoenfelder et al. 2010). A comprehensive description of the
three-dimensional structure of the erythroid progenitor nucleus
by chromosome conformation capture–based technologies will
be necessary to gain global insights into these phenomena
(Lieberman-Aiden et al. 2009). Nevertheless, we hypothesize
that some of these sites of chromatin occupancy where the
target gene was ambiguous might represent the promoters of
previously uncharacterized erythroid transcripts. Surprisingly,
recent efforts to survey transcription across different tissues, such
as the Illumina Human Body Map version 2, have not included
erythroid progenitor cells in the tissue sets interrogated (Cabili
et al. 2011). We identified from our mRNA-seq data two previously
undescribed geneswehave designated Lincred1 and Lincred2 (Fig. 4).
We hypothesize that these genes are likely to produce noncod-
ing RNAs based on the absence of substantial ORFs in their se-
quences. While we are yet to describe their precise function or
mechanism of action, the up-regulation of Lincred1 and Lincred2
during the terminal stages of erythropoiesis suggests function. The
fact that these noncoding genes are also regulated byKLF1,GATA1,
and TAL1 indicates that they are likely to play a significant role in
erythropoiesis. Not unexpectedly another class of noncoding
RNAs, themiRs, have recently been shown to perform critical roles
in terminal erythroid differentiation (Rasmussen et al. 2010;
Zhang et al. 2011). It is likely that KLF1 also plays a role in reg-
ulating mammalian miRs since the zebrafish Klf, Klfd, has been
shown to regulate expression of zebrafishmir144; however, small
molecule RNA-seq would be required to properly address this
question (Fu et al. 2009).
Klf1/ embryos have previously been shown to have defects
in b-like globin gene expression, formation of an appropriate cell
membrane and cytoskeletal structure, and a distorted cell cycle
program (Nuez et al. 1995; Perkins et al. 1995; Drissen et al. 2005;
Hodge et al. 2006; Tallack et al. 2007, 2009; Pilon et al. 2008). Each
Figure 4. KLF1 regulates two novel erythroid-specific long noncoding RNAs (lncRNAs). (A) An image from the UCSC Genome Browser with tracks
depicting a novel long intergenic noncoding RNA of erythroid differentiation defined as Lincred1. (Red) Erythroid RNAs present in this region as defined by
Cufflinks. There appears to be two separate isoforms of the one gene; hence, they have been named ‘‘giant’’ and ‘‘dwarf ’’ for the long and short isoforms,
respectively. (Black) Mouse mRNAs and ESTs deposited into GenBank for this same region. Representative mRNA-seq tracks for a single Klf1/ and Klf1+/+
are shown in light blue and orange, respectively (all mRNA-seq data are presented in Supplemental Fig. S6). ChIP-seq data for KLF1, GATA1, and TAL1
(maroon tracks), as well as CTCF and EP300 (dark blue tracks), from erythroid tissues are shown together with peak calls. (Bottom) A vertebrate con-
servation track (phyloP). Exons of the novel lncRNAs are highlighted by vertical gray bars. (B) An image from the UCSC Genome Browser for the novel
erythroid lncRNA Lincred2. Tracks in the browser image are as described above for A. (C ) Quantification of mRNA-seq data for Lincred1-giant, Lincred1-
dwarf, and Lincred2 by the FPKM method. Each bar represents the mean FPKM for three independent biological replicates + 95% confidence interval.
(*) Benjamini-Hochberg–corrected P < 0.05. (D) Expression validation by qRT-PCR using specific primers for Lincred1 and Lincred2. Each bar represents the
mean + SEM for at least three independent biological replicates normalized to the housekeeping gene HPRT and to the Klf1+/+ expression level. (***) P <
0.001 by Student’s t-test. Note that primers for Lincred1 amplify both the giant and dwarf isoforms. (E ) Representative FACS plot for sorting E13.5 fetal liver
cells into R1–R5 populations using the cell surface markers CD71 and TER119. Gates are shown together with the proportion of cells in each population.
(F ) Expression of Lincred1 throughout erythroid differentiation (R1–R5) as determined by qRT-PCR. Each point shown is the mean 6 SEM for three
independent biological replicates normalized to expression of the housekeeping gene HPRT. (G) Expression of Lincred2 throughout erythroid differen-
tiation shown as above in F.
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of these phenotypes contributes to the severe anemia of Klf1/
embryos; however, the perturbations to gene expression are more
dramatic than these pathways alone (Supplemental Table S5). In
particular, we noticed that the loss of Klf1 was associated with the
decreased expression of apoptotic genes (Supplemental Table S5).
Since we observed a decrease in expression of Bcl2l1 and an in-
crease in Bcl2l11, we expected to find increased apoptosis in the
fetal livers of Klf1/ embryos (Fig. 5A,C). This was not found to be
the case and seems at odds with the increased levels of the 17-kD
form of caspase 3 that we observed in Klf1/ fetal livers (Fig. 5B).
Similar perturbations to the apoptotic pathway are found in
Gata1/ and Zbtb7a/ mice; however, these embryos do have
increased numbers of apoptotic cells (Maeda et al. 2009). It is
particularly interesting that in addition to regulating apoptosis,
caspase 3, BCL2L1, and BCL2L11 all appear to play critical roles
in erythropoiesis (Wagner et al. 2000; Zermati et al. 2001; Maeda
et al. 2009). We suggest that in the absence of Klf1, genes of the
apoptotic program have been disrupted sufficiently to prevent
terminal erythroid differentiation, but perhaps not to a level
sufficient to complete the final apoptosis pathway. This phe-
notype of failed terminal erythroid differentiation in Klf1/
mice is reminiscent of the pathology of CDA in human patients
resulting from KLF1 mutations whereby immature nucleated
erythroid cells are released into the blood stream (Arnaud et al.
2010).
In summary, we have presented here a comprehensive set of
KLF1-dependent erythroid genes in addition to novel insights into
KLF1’s mechanism of action as a transcriptional activator. We
suggest that KLF1 cooperateswith the transcription factorsGATA1,
TAL1 and the coactivator EP300 at 75 sites in the erythroid ge-
nome to regulate erythroid-specific levels of gene expression, in
some cases via previously uncharacterized erythroid promoters.
We also report here the discovery of two novel lncRNAs with
erythroid-specific expression that are KLF1-dependent and describe
that perturbation to the apoptotic gene expression program inKlf1/
mice does not result in apoptosis but is likely to contribute to a failure
of terminal erythroid differentiation.
Methods
mRNA-seq library preparation and sequencing
Fetal liver tissue from E14.5 Klf1+/ 3 Klf1+/ timed matings
was collected, homogenized, and preserved in TRIzol reagent
(Invitrogen). Genotyping was performed by PCR according to
the method previously described (Hodge et al. 2006). Total RNA
was collected as per the manufacturer’s recommendations and
depleted of alpha-globin and beta-globin mRNA using the
Mouse/Rat GLOBINclear Kit (Ambion) starting with 10 mg
DNase I (Invitrogen) treated RNA. Three Klf1+/+ and three Klf1/
samples from two independent litters were selected and used to
prepare mRNA-seq libraries using the mRNA-Seq Sample Prep Kit
(Illumina). Each library was sequenced in a separate lane using
the GAII sequencing platform (Illumina) to obtain >20 3 106
single-end 76-bp reads. Raw reads have been deposited in
the Gene Expression Omnibus (GEO) under accession no.
GSE33979.
mRNA-seq mapping, expression, and transcript construction
mRNA-seq reads were mapped to the mm9 genome of UCSC
(ftp://ftp.cbcb.umd.edu/pub/data/bowtie_indexes/mm9.ebwt.zip)
to generate six BAM files individually using Tophat-1.3.1 (http://
tophat.cbcb.umd.edu/downloads/) (Trapnell et al. 2009). Sub-
sequently, the six BAM files were imported to Cuffdiff of
Cufflinks-1.0.3 (http://cufflinks.cbcb.umd.edu/downloads/) with
a set of RefSeq annotated transcripts in GTF format (ftp://igenome:
G3nom3s4u@ftp.illumina.com/Mus_musculus/UCSC/mm9/Mus_
Figure 5. Loss of Klf1 disrupts the normal apoptotic program. (A) Ex-
pression of Bcl2l1 and Bcl2l11 by qRT-PCR in E14.5 fetal liver normalized to
the housekeeping gene HPRT. Each bar shown is the mean + SEM for at
least three independent biological replicates. (*) P < 0.05 by Student’s
t-test. Klf1+/? is used to indicate that both Klf1+/+ and Klf1+/ samples were
considered together. (B) Western blot analysis of whole-cell protein ex-
tracts for different Klf1 genotypes as indicated. Protein levels of caspase 3
(CASP3) and PARP1 were investigated using specific antibodies with
GATA1 as a loading control. Expected cleavage products of caspase 3 and
PARP1 are shown by a left-facing arrow and asterisk, respectively. (C )
Representative TUNEL assay FACS plots for Klf1+/+ and Klf1/ genotypes
as indicated. Cells were co-stained for TUNEL and the erythroid marker
CD71. The percentages of cells staining TUNEL positive are indicated.
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musculus_UCSC_mm9.tar.gz) to conduct differential gene ex-
pression tests (Trapnell et al. 2010; Roberts et al. 2011a,b).
We defined differentially expressed genes as either KLF1
‘‘activated’’ or KLF1 ‘‘repressed’’ for genes with significantly
greater expression in the Klf1+/+ or Klf1/ samples, respectively.
We used a mean Klf1+/+ FPKM cutoff of 0.5 to ensure genes in our
lists were sufficiently expressed in the E14.5 fetal liver, and only
reported genes with a greater than 1.5-fold difference in mean
FPKM between the Klf1+/+ and Klf1/ genotypes. All of the genes
reported in our gene lists were found to be significantly dif-
ferentially expressed between the genotypes by Cuffdiff after
a Benjamini-Hochberg correction for multiple-testing errors
(P < 0.05).
The lncRNAs Lincred1-giant, Lincred1-dwarf, and Lincred2
were assembled using the de novo transcript assembly tool
Cufflinks-1.0.3. Differential gene expression data for these tran-
scripts was also obtained using the Cuffdiff component of the
Cufflinks suite.
Quantitative real-time RT-PCR
Fetal liver total RNA was collected using TRIzol reagent (Invitro-
gen) and reverse transcribed to cDNA using Superscript III reverse
transcriptase (Invitrogen). qRT-PCR was performed using the
7900HT Fast Real-Time PCR System (Applied Biosystems) using
SYBRGreen chemistry (Applied Biosystems) with transcript-specific
primers described in Supplemental Table S6.
Western blotting
Fetal liver whole-cell protein extracts were prepared using RIPA
buffer and resolved on 4%–12% Bis-Tris precast gels (Invitrogen).
Blottingwas performed by transferring proteins to PVDFmembrane
(GE Healthcare), blocking, and incubating with the appropriate
primary and ECL-conjugated secondary antibodies. The primary
antibodies usedwere as follows: anti-caspase 3, 9661Cell Signaling
Technology; anti-GATA1, sc-265 Santa Cruz Biotechnology; and
anti-PARP, MCA1522G AbD Serotec.
TUNEL assay
Homogenized E14.5 fetal livers were assayed for apoptosis using
the TUNEL method. Cells were prepared according to the manu-
facturer’s recommendations using the In Situ Cell Death Detection
Kit, Fluorescein (Roche); co-stained with CD71-PE (BD Pharmin-
gen); and analyzed using a FACSCanto II flow cytometer (BD) and
FlowJo software (Treestar).
Fetal liver cell sorting (R1–R5)
Homogenized E13.5 fetal livers from wild-type BALB/c timed
matings were dual stained with CD71-FITC (BD Pharmingen) and
TER119-PE (BD Pharmingen) and sorted into R1–R5 populations
according to the method described by Zhang et al. (2003) using an
Influx Cell Sorter (BD Cytopeia). Greater than 500,000 cells were
collected for each population on three separate occasions and used
to generate cDNA for qRT-PCR as described above.
ChIP-seq peak overlap analysis
Analysis of ChIP-seq peak overlap for KLF1, GATA1, TAL1, and
EP300 was performed according to the method previously de-
scribed (Tallack et al. 2010) using the data sets of Tallack et al.
(2010), Cheng et al. (2009), Kassouf et al. (2010), and ENCODE/
Stanford/Yale, respectively. Essentially we considered peaks to
‘‘overlap’’ where the ends of the features were within 500 bp of
each other.
ChIP-seq peak to TSS lists and distributions
In order to match-up a KLF1 binding event (peak) with a corre-
sponding function, we paired KLF1 peaks (all peaks or sets of peaks
selected based on EP300 co-occupancy) to the closest TSS for dif-
ferentially expressed genes identified bymRNA-seq.We performed
these analyses for the KLF1 ‘‘activated’’ (690 genes) and KLF1 ‘‘re-
pressed’’ (118 genes) sets of genes considering all RefSeq annotated
TSSs for these genes. By use of the online Galaxy Genomics Server
(http://main.g2.bx.psu.edu/) (Giardine et al. 2005; Blankenberg
et al. 2010; Goecks et al. 2010), we started with each of the KLF1
peak centers and searched for the closest TSS in either direction
from the appropriate gene list (either ‘‘activated’’ or ‘‘repressed’’).
This allowed us to generate a list of putative KLF1 activation and
KLF1 repression genomic interactions including the specific dis-
tance of such interaction. By use of these lists, we generated cu-
mulative frequency distributions to gain global insights into KLF1
function. In creating KLF1 activation and KLF1 repression lists
and distributions, we performed the same analysis 10 times on
randomly selected lists of 690 or 118 (for activation and repression,
respectively) genes and generated the mean distribution of these
simulated analyses to serve as a control. This analysis allowed us to
ascertain whether a proximity relationship between KLF1 binding
(ChIP-seq peaks) and gene activation or repression existed or
whether the distribution of distances was random. For the EP300
analysis, the KLF1 peaks were separated into two sets, KLF1 only
and EP300 shared, and each of these sets was used to determine the
closest ‘‘activated’’ TSS and plot the distributions.
Gene Expression Atlas analysis
Weused theArrayExpressArchive (http://www.ebi.ac.uk/arrayexpress/)
to download the human gene expression atlas representing 79
different cell and tissue types each in duplicate (E-TABM-145) (Su
et al. 2004; Vaquerizas et al. 2009). This study was performed using
the HG-U133A GeneChip human genome array (Affymetrix) to
survey for tissue specific gene expression. The sample designated
‘‘CD71+ early erythroid’’ was the best indicator of erythroid-
specific gene expression. We used these data to look for genes
that were broadly expressed at a background level with higher
levels of expression in the duplicate ‘‘CD71 early erythroid’’
samples. Expression of the transcription factor Klf3, which is
known to follow this pattern served as a good example (Funnell
et al. 2007).
GO enrichment analysis
The online GO tool DAVID (http://david.abcc.ncifcrf.gov/) was
used to determine enriched GO terms in the KLF1 ‘‘activated’’ and
KLF1 ‘‘repressed’’ gene sets (Huang da et al. 2009a,b). We used the
Gene Functional Classification tool from the DAVID suite to
cluster enriched GO terms (biological process, molecular function,
and cellular compartment) with the classification stringency set to
medium and all other options default.
Motif enrichment analysis using MEME-ChIP
We performed a motif enrichment analysis using the de novo
motif identification tool MEME-ChIP ( http://meme.sdsc.edu/)
for the KLF1 only and EP300 shared sets of peaks (Machanick and
Bailey 2011). Our extended peak regions (described above in
‘‘ChIP-seq Peak Overlap Analysis’’) served as the input for MEME-
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ChIP and were ‘‘trimmed’’ to obtain the central 100 bp of se-
quence for each peak. We used the following parameters: distri-
bution of motif occurrences, zero or one per sequence; number
of different motifs, 5; minimum motif width, 4; and maximum
motif width, 30.
Data access
mRNA-seq data reported in this study have been deposited into the
NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.
nih.gov/geo/) under accession number GSE33979. The previously
published ChIP-seq data for KLF1 are also available in the same
database under accession number GSE20478 (Tallack et al. 2010).
The sequences of the novel lncRNAs described here have been
deposited into GenBank (http://www.ncbi.nlm.nih.gov/genbank)
with the following accession numbers: Lincred1-giant, JQ173108;
Lincred1-dwarf, JQ173109; Lincred2, JQ173110.
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